Status:
RECRUITING
Determining the Effect of Six Weeks of Cannabis Abstinence on Fronto- Striatal fMRI Markers in Adolescents With Cannabis Use Disorder (ABSCAN)
Lead Sponsor:
University of Minnesota
Conditions:
Cannabis Use Disorder
Eligibility:
All Genders
15-18 years
Phase:
NA
Brief Summary
The goal of this study is to understand the changes in neural correlates of reward in adolescents with and without Cannabis Use Disorder (CUD). The study will collect functional magnetic resonance ima...
Eligibility Criteria
Inclusion
- Male and female adolescents between the ages of 15 and 18 (inclusive).
- Have a parent or legal guardian who is able and willing to provide written informed consent.
- Competent and willing to provide written informed assent (participants \<18) or consent (participants=18).
- Native English speaker.
- Have a parent or legal guardian who is fluent in English.
- Able to commit to 8 study visits in approximately 60 days (6 weeks).
- Able to safely participate in the protocol and appropriate for outpatient level of care, in the opinion of the PI.
- No active psychosis or current use of antipsychotic medications.
- Participants taking psychotropic medications will be included if the medications have been stable for 6 weeks and are expected to remain stable for the duration of their study participation (i.e., through the third MRI).
- For CB-Abst (n=24) and CB-Mon (n=20) groups: at least 5 days of use per week on average in the past two months and meet DSM-V cannabis use disorder (CUD; at least Mild) criteria. Cannabis use reported within seven days of baseline visit. Positive qualitative urine toxicology test at baseline for THC. No immediate plan to discontinue cannabis use.
- For Con (n=20): no lifetime history of cannabis use. Negative qualitative urine toxicology test at baseline for THC. No immediate plans to begin cannabis use.
- For optional components (A: daily remote assessments during and/or (B) after treatment period): access to a personal device (e.g., smartphone or computer) on which to complete daily remote assessments.
Exclusion
- Past twelve-month history of substance use disorders (except for Cannabis Use Disorder in CB-Abst and CB-Mon), assessed via semi-structured psychodiagnostics interview at baseline.
- Current daily nicotine use (e.g., via electronic and/or combustible cigarettes).
- Contraindications for MRI (ascertained via participant and parent report), including but not limited to:
- Metal implants such as surgical clips or pacemakers, or history of working with metal, unless the possibility of a metal fragment can be ruled out by recent orbital scans.
- Prior head trauma with neurological sequelae.
- Claustrophobia.
- Weight incompatible with MRI safety.
- Pregnancy.
- Previous or current diagnosis of psychosis, cognitive disability, or bipolar disorder.
- Active suicidality.
- Taking a psychotropic medication that has not reached stability criterion (same medication type and dose for 6 weeks with no planned changes over the study period).
- Any other medical or psychiatric condition deemed serious or contraindicated for any study procedures by Dr. Tervo-Clemmens.
Key Trial Info
Start Date :
April 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 15 2028
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT06124846
Start Date
April 1 2024
End Date
April 15 2028
Last Update
August 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Minnesota
Minneapolis, Minnesota, United States, 55414